hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06312215, orgStudyIdInfo id: 1763831, briefTitle: Effect Of Open And Closed System Peripheral Catheters Used In Pediatric Services, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-26, primaryCompletionDateStruct date: 2023-10-02, completionDateStruct date: 2023-10-02, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Tarsus University, class: OTHER, descriptionModule briefSummary: The study was conducted as a randomized controlled experimental research to examine the effects of open and closed system peripheral catheters on the success of insertion, duration of stay, and development of complications in children aged 1-18 years in pediatric services. The population of the study consisted of children admitted to the Pediatric Services of the Istanbul Faculty of Medicine, and the sample included a total of N=80 children who met the sample criteria and underwent catheter insertion between May 2023 and October 2023. The sample was divided into two groups: closed system peripheral venous catheter group (n=40) and open system peripheral venous catheter group (n=40). The data of the study were collected using a Data Collection Form, Peripheral Venous Catheter Monitoring Form, Visual Infusion Phlebitis Detection Scale, and Pediatric Peripheral Intravenous Infiltration Scale, conditionsModule conditions: Child, Only, conditions: Catheter Infection, conditions: Catheter Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 80, type: ACTUAL, armsInterventionsModule interventions name: Closed-system catheter, outcomesModule primaryOutcomes measure: Patient Identification Form, primaryOutcomes measure: Daily Monitoring Form, primaryOutcomes measure: Visual Infusion Phlebitis Assessment Scale, Staging Key - Peripheral IV'sVIPAS, primaryOutcomes measure: Pediatric peripheral intravenous infiltration assessment tool, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Tarsus University, city: Mersin, zip: 33400, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06312202, orgStudyIdInfo id: DROWN_HARBOUR, briefTitle: Drowning Incidents in Danish Harbours, acronym: DROWN_HARBOR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Prehospital Center, Region Zealand, class: OTHER, descriptionModule briefSummary: A recent study reported significantly increased mortality from drowning-related out-of-hospital cardiac arrest in Danish harbours compared to other public places (e.g., public pools, coastlines, and lakes). Accurate and reliable data are necessary before establishing specific educational, preventative, rescue, or treatment strategies to reduce the number of drowning incidents in Danish harbours and improve survival. Therefore, it is essential to characterise drowning incidents in Danish harbours and analyse risk factors associated with fatal drowning., conditionsModule conditions: Drowning, conditions: Drown, conditions: Drowning; Anoxia, conditions: Drowning, Near, conditions: Drowning; Asphyxia, conditions: Drowning and Nonfatal Submersion, conditions: Drowning or Immersion of Unknown Intent, conditions: Drowning and Submersion, Undetermined Intent, conditions: Drowning and Submersion While in Natural Water, conditions: Drowning and Submersion Due to Sailboat Sinking, conditions: Drowning and Submersion Due to Fall Off Ship, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Drowning, outcomesModule primaryOutcomes measure: Yearly incidence of drowning incidents, primaryOutcomes measure: Fatal to non-fatal drowning ratio, secondaryOutcomes measure: Assess risk factors associated with 30-day mortality, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Prehospital Center, city: Næstved, state: Region Zealand, zip: 4700, country: Denmark, geoPoint lat: 55.22992, lon: 11.76092, hasResults: False
protocolSection identificationModule nctId: NCT06312189, orgStudyIdInfo id: NBI-98854-HD3022, briefTitle: Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Neurocrine Biosciences, class: INDUSTRY, descriptionModule briefSummary: This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada., conditionsModule conditions: Chorea, Huntington, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 7, type: ESTIMATED, armsInterventionsModule interventions name: Valbenazine, outcomesModule primaryOutcomes measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Neurocrine Clinical Site, city: Vancouver, state: British Columbia, zip: V6T 2B5, country: Canada, geoPoint lat: 49.24966, lon: -123.11934, locations facility: Neurocrine Clinical Site, city: Ottawa, state: Ontario, zip: K1Y 4E9, country: Canada, geoPoint lat: 45.41117, lon: -75.69812, locations facility: Neurocrine Clinical Site, city: Toronto, state: Ontario, zip: MK2 1E1, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06312111, orgStudyIdInfo id: 62/2021, briefTitle: Physical Activity and Various Aspects of Quality of Life in Patients With Pulmonary Arterial Hypertension (Ph-PAH), acronym: PhA-PAH, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-04-22, primaryCompletionDateStruct date: 2021-07-15, completionDateStruct date: 2022-07-17, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Centre of Postgraduate Medical Education, class: OTHER, descriptionModule briefSummary: Evaluate whether education, a simple doctor's recommendation to increase physical activity in inactive patients, and self-monitoring of physical activity using a pedometer were effective and beneficial for patients with pulmonary arterial hypertension (PAH), conditionsModule conditions: Pulmonary Arterial Hypertension, conditions: Physical Inactivity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ACTUAL, armsInterventionsModule interventions name: recommendation to increase physical activity, outcomesModule primaryOutcomes measure: Number of steps per day, secondaryOutcomes measure: Change in 6-minute walk distance, secondaryOutcomes measure: Change in quality of life (SF-36), secondaryOutcomes measure: Change in the hospital anxiety and depression scale (HADS), secondaryOutcomes measure: Change in the acceptance of illness (AIS), secondaryOutcomes measure: Change in N-Terminal Pro-B-Type Natriuretic Peptide level (NT-proBNP), secondaryOutcomes measure: Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWD, secondaryOutcomes measure: Compliance with counting steps, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, European Health Centre, Otwock, Centre of Postgraduate Medical Education, city: Otwock, state: Borowa 14/18, zip: 05-400, country: Poland, geoPoint lat: 52.10577, lon: 21.26129, hasResults: False
protocolSection identificationModule nctId: NCT06312098, orgStudyIdInfo id: KC21RISI0576, briefTitle: Perioperative Factors and Living Donor Liver Transplantation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Min Suk Chae, class: OTHER, descriptionModule briefSummary: Liver transplant surgery is one of the treatments provided to patients suffering from end-stage liver disease, and has a successful treatment prognosis. However, it is clear that patient management before, during, and after surgery is a difficult task for medical staff due to the complex clinical and pathological problems of end-stage liver disease. Moreover, the complex surgical technique of the liver transplant surgery itself and the severe hemodynamic fluctuations and multi-organ dysfunction that patients experience during the surgery have been shown to have a tremendous impact on the patient's prognosis after surgery.A study on which clinical, laboratory, and hemodynamic factors experienced by patients during the perioperative period, including before, during, and after surgery, affect the survival rate of patients and transplanted organs. will definitely be helpful in the treatment of patients suffering from end-stage liver disease., conditionsModule conditions: Liver Transplant Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 533, type: ESTIMATED, armsInterventionsModule interventions name: remote ischemic preconditioning (RIPC), outcomesModule primaryOutcomes measure: Incidence of postreperfusion syndrome, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 79 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06312085, orgStudyIdInfo id: EF_5301_V1.0_CIP, briefTitle: A Study to Assess the Clinical Success of Root Canal Treatment Using Novel Obturation Material., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Lumendo AG, class: INDUSTRY, collaborators name: Avania, descriptionModule briefSummary: The goal of this study is prospective, single-arm, non-randomized controlled trial to test the effectiveness, safety and performance of a novel dental obturation material. The main question sit answers is1. To test the effectiveness of the Endofill device for root canal obturation up to 12-month follow-up period.2. To test the performance of the Endofill device evaluated with periapical radiographs immediately on completion of procedure.The participants requiring root canal treatment will be treated with obturated using Endofill material and post-treatment follow-up vistis will be conducted for 1 year. This is a single-arm study with no comparison groups., conditionsModule conditions: Endodontic Treatment, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 63, type: ESTIMATED, armsInterventionsModule interventions name: Endofill, outcomesModule primaryOutcomes measure: Effectiveness of root canal treatment using Endofill, secondaryOutcomes measure: Safety of root canal treatment using endofill, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medipol University, city: Istanbul, country: Turkey, contacts name: Tan Firat Eyuboglu, role: CONTACT, phone: +905304636059, email: tfeyuboglu@yahoo.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06312059, orgStudyIdInfo id: KNC-GMS-002, briefTitle: Goat or Cow Milk Based Infant Formula GMS, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-14, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-08-15, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Kendal Nutricare Ltd, class: INDUSTRY, collaborators name: ObvioHealth, descriptionModule briefSummary: This study is a non-inferiority, decentralized, randomized, double-blind, controlled clinical trial evaluating the growth, tolerance, and safety of a goat's-milk test infant formula (Test Formula 1; TF1) and a cow's-milk test infant formula (Test Formula 2; TF2), each compared to a cow's-milk infant formula commercially available in the United States (Control Formula; CF)., conditionsModule conditions: Growth, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: QUADRUPLE, maskingDescription: RP Over stickered TP in blank packaging., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 264, type: ESTIMATED, armsInterventionsModule interventions name: "Similac® Advance Infant Formula Powder, interventions name: "Kendamil Cow milk test product, interventions name: "Kendamil goat milk test product, outcomesModule primaryOutcomes measure: Growth as compared against WHO growth charts, secondaryOutcomes measure: Safety, otherOutcomes measure: Tolerability- Monitoring of stool consistency, otherOutcomes measure: Tolerability - fussiness, otherOutcomes measure: Mean Daily Recumbent Length Gain, otherOutcomes measure: Mean Daily Head Circumference Gain, eligibilityModule sex: ALL, maximumAge: 14 Days, stdAges: CHILD, contactsLocationsModule locations facility: ObvioHealth USA, Inc., status: RECRUITING, city: New York, state: New York, zip: 10001, country: United States, contacts name: Parth Shah, role: CONTACT, phone: 513-571-5377, email: parth.shah@obviohealth.com, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06312007, orgStudyIdInfo id: UH23030202, briefTitle: Semi-seated Holding Position to Reduce Stress Responses in in the Neonatal Intensive Care Unit, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2023-11-01, completionDateStruct date: 2023-12-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Hasanuddin University, class: OTHER, descriptionModule briefSummary: This study to compare half semi seated position and side lying position with cortisol level on the neonate's stress respon, conditionsModule conditions: Semi Seated Position, conditions: Side Lying Position, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Intervention semi seated position Control side lying position, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ACTUAL, armsInterventionsModule interventions name: Semi seated position, interventions name: side lying position, outcomesModule primaryOutcomes measure: Kortisol level, primaryOutcomes measure: Oxytocin level, eligibilityModule sex: ALL, minimumAge: 32 Weeks, maximumAge: 42 Weeks, stdAges: CHILD, contactsLocationsModule locations facility: Hasanuddin University, city: Makassar, state: South Sulawesi, country: Indonesia, geoPoint lat: -5.14861, lon: 119.43194, hasResults: False
protocolSection identificationModule nctId: NCT06311981, orgStudyIdInfo id: SPHIC-TR-THLC2023-08, briefTitle: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-06-17, completionDateStruct date: 2026-06-17, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Jian Chen, class: OTHER, descriptionModule briefSummary: To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy., conditionsModule conditions: Non-small Cell Lung Cancer, conditions: Older People, conditions: Carbon Ion Radiotherapy, conditions: Radiotherapy Side Effect, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 29, type: ESTIMATED, armsInterventionsModule interventions name: carbon ion radiotherapy, interventions name: targeted therapy, interventions name: single regimen chemotherapy in sequence with radiotherapy, outcomesModule primaryOutcomes measure: Disease progression-free survival rate, primaryOutcomes measure: Incidence of Treatment-induced Adverse Events, secondaryOutcomes measure: Local control rate, secondaryOutcomes measure: Cause-specific survival rate, secondaryOutcomes measure: Overall survival rate, eligibilityModule sex: ALL, minimumAge: 75 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Proton and Heavy Ion Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 201513, country: China, contacts name: Jing Li, role: CONTACT, phone: 86-21-38296678, email: jing.li@sphic.org.cn, contacts name: Kun Liu, role: CONTACT, phone: 86-21-38296678, email: kun.liu@sphic.org.cn, contacts name: Jian Chen, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Jingfang Mao, PHD, role: PRINCIPAL_INVESTIGATOR, contacts name: Kai-liang Wu, PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06311968, orgStudyIdInfo id: SPHIC-TR-THLC2023-07, briefTitle: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2027-02-28, completionDateStruct date: 2027-02-28, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Jian Chen, class: OTHER, descriptionModule briefSummary: To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival., conditionsModule conditions: Thymus Epithelial Tumor, conditions: Proton Radiotherapy, conditions: Radiation Toxicity, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 55, type: ESTIMATED, armsInterventionsModule interventions name: Proton radiotherapy, interventions name: combined platinum based chemotherapy, outcomesModule primaryOutcomes measure: Disease progression-free survival rate, primaryOutcomes measure: Incidence of Treatment-induced Adverse Events, secondaryOutcomes measure: Overall survival rate, secondaryOutcomes measure: Cause-specific survival rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Proton and Heavy Ion Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 201513, country: China, contacts name: Jing Li, role: CONTACT, phone: 86-21-38296678, email: jing.li@sphic.org.cn, contacts name: Kun Liu, role: CONTACT, phone: 86-21-38296678, email: kun.liu@sphic.org.cn, contacts name: Jian Chen, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Jingfang Mao, PHD, role: PRINCIPAL_INVESTIGATOR, contacts name: Kai-liang Wu, PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06311955, orgStudyIdInfo id: SPHIC-TR-THLC2023-06, briefTitle: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-02-28, completionDateStruct date: 2029-02-28, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Jian Chen, class: OTHER, descriptionModule briefSummary: To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival., conditionsModule conditions: Thymic Epithelial Tumor, conditions: Radiotherapy Side Effect, conditions: Carbon Ion Radiotheray, conditions: Heavy Ion Radiotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Carbon ion radiotherapy, interventions name: combined with platinum-based regimen, outcomesModule primaryOutcomes measure: Disease progression-free survival rate, primaryOutcomes measure: Incidence of Treatment-induced Adverse Events, secondaryOutcomes measure: Local-progression free survival rate, secondaryOutcomes measure: Overall survival rate, secondaryOutcomes measure: Cause-specific survival rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Proton and Heavy Ion Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 201513, country: China, contacts name: Jing Li, role: CONTACT, phone: 86-21-38296678, email: jing.li@sphic.org.cn, contacts name: Kun Liu, role: CONTACT, phone: 86-21-38296678, email: kun.liu@sphic.org.cn, contacts name: Jian Chen, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Jingfang Mao, PHD, role: PRINCIPAL_INVESTIGATOR, contacts name: Kai-liang Wu, PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False